Cost of cancer care for patients undergoing chemotherapy: the Elements of Cancer Care study

Ward, Robyn L., Laaksonen, Maarit A., van Gool, Kees, Pearson, Sallie-Anne, Daniels, Ben, Bastick, Patricia, Norman, Richard, Hou, Changhao, Haywood, Philip and Haas, Marion (2015) Cost of cancer care for patients undergoing chemotherapy: the Elements of Cancer Care study. Asia Pacific Journal Clinical Oncology, 11 2: 178-186. doi:10.1111/ajco.12354


Author Ward, Robyn L.
Laaksonen, Maarit A.
van Gool, Kees
Pearson, Sallie-Anne
Daniels, Ben
Bastick, Patricia
Norman, Richard
Hou, Changhao
Haywood, Philip
Haas, Marion
Title Cost of cancer care for patients undergoing chemotherapy: the Elements of Cancer Care study
Journal name Asia Pacific Journal Clinical Oncology   Check publisher's open access policy
ISSN 1743-7563
1743-7555
Publication date 2015-06
Sub-type Article (original research)
DOI 10.1111/ajco.12354
Open Access Status Not Open Access
Volume 11
Issue 2
Start page 178
End page 186
Total pages 9
Place of publication Chichester, West Sussex, United Kingdom
Publisher Wiley-Blackwell
Language eng
Formatted abstract
Aim: To determine the monthly treatment costs for each element of cancer care in patients receiving chemotherapy and to apportion the burden of cost by financing agent (Commonwealth, State government, private health insurer, patient).

Methods: A cohort of 478 patients (54% breast, 33% colorectal and 13% non-small-cell lung cancer) were recruited from 12 centers representing metropolitan and regional settings in public and private sectors. Primary data were linked to secondary data held in New South Wales state (Admitted Patients and Emergency Department Data) and Commonwealth (Medicare and Pharmaceutical Benefits) databases. The monthly treatment costs of each element of care and the funding agent were calculated from secondary health data.

Results: Across all tumor types, the mean monthly treatment cost was $4162 (10%-90% quantiles $1018-$8098; range $2853 [adjuvant colorectal] to $5622 [metastatic lung]), with 54% of this cost borne by Commonwealth government, 26% by private health insurers, 14% by State government and 6% by patients. The mean monthly costs of treating metastatic disease were $1415 greater than those for adjuvant therapy. The mean monthly costs were contributed to by inpatient care ($1657, 40%), chemotherapy prescriptions ($1502, 36%), outpatient care ($452, 11%) and administration of chemotherapy ($364, 9%).

Conclusion: All four funders have a shared incentive to reduce absolute monthly treatment costs since their proportional contribution is relatively constant for most tumor types and stages. There are opportunities to reduce cancer care costs by minimizing the risk of inpatient hospital admissions that arise from chemotherapy administration and by recognizing incentives for cost-shifting.
Keyword Breast neoplasm
Colorectal neoplasm
Cost and cost analysis
Drug therapy
Lung neoplasm
Q-Index Code C1
Q-Index Status Provisional Code
Institutional Status Non-UQ

Document type: Journal Article
Sub-type: Article (original research)
Collection: School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 2 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 2 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Wed, 27 Jul 2016, 14:58:30 EST by Amelie Casgrain on behalf of School of Medicine